<abstract xmlns="http://www.w3.org/1999/xhtml"><p> The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases. We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, &lt;1/10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately e calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.</p></abstract>

The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases. We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1/10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately e calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

Department of Dermatology, Military Institute of Medicine, Warsaw, Poland

Department of Applied Pharmacy, Medical University of Lublin, Poland

Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland

Department of Functional Research, Institute of Rural Health in Lublin, Poland

Chair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Poland

Department of Materials Engineering, Lublin University of Technology, Poland

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side...

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

Published Online: May 30, 2014

Page range: 32 - 36

Received: Mar 17, 2014

Accepted: Mar 24, 2014

DOI: https://doi.org/10.2478/cipms-2014-0009

Keywords
health care costs, adverse drug events, pulmonary medicine

© 2014

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

Published Online: May 30, 2014

Page range: 32 - 36

Received: Mar 17, 2014

Accepted: Mar 24, 2014

DOI: https://doi.org/10.2478/cipms-2014-0009

Keywordshealth care costs, adverse drug events, pulmonary medicine

© 2014

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Keywords
health care costs, adverse drug events, pulmonary medicine